Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of autologous adipose-derived mesenchymal stem cells for bronchopleural fistula
2012-000292-16Phase 2Active
- Sponsor
- FIBHULP
- Start
- Apr 2013
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in bronchopleural fistula (BPF), sponsored by FIBHULP. Primary endpoints: Safety and feasibility at 3 and 6 months and Cumulative incidence of adverse events attributed to study therapy. Started Apr 2013; status: active.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
bronchopleural fistula (BPF)
Beyond the preview
Go deeper on 2012-000292-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000292-16.